Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | RORC | P51449 | 3/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | NOTCH1 | P46531 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277789 | 0.90 | PDE4B (0.57) | TACR1PDE4BRORCUSP30 | |
| SCHEMBL10277788 | 0.90 | PDE4B (0.57) | TACR1PDE4BRORCUSP30 | |
| SCHEMBL10277792 | 0.90 | PDE4B (0.57) | TACR1PDE4BRORCUSP30 | |
| SCHEMBL2242591 | 0.88 | GPR119 (0.54) | TACR1PDE4BRORCUSP30GPR119 | |
| SCHEMBL2248421 | 0.88 | GPR119 (0.54) | TACR1PDE4BRORCUSP30GPR119 | |
| SCHEMBL8265507 | 0.88 | TACR1 (0.53) | TACR1PDE4BRORCUSP30GPR119 | |
| SCHEMBL2242454 | 0.88 | GPR119 (0.54) | TACR1PDE4BRORCUSP30GPR119 | |
| SCHEMBL2240929 | 0.88 | GPR119 (0.54) | TACR1PDE4BRORCUSP30GPR119 | |
| SCHEMBL953506 | 0.87 | TACR1 (0.61) | TACR1PDE4BRORCUSP30GPR119 | |
| SCHEMBL2239870 | 0.87 | TACR1 (0.61) | TACR1PDE4BRORCUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | TACR1 433/4885PDE4B 457/4885RORC 1096/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | TACR1 475/4885PDE4B 543/4885RORC 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.